OverviewSuggest Edit

SpringWorks Therapeutics is a mission-driven medicines company dedicated to developing innovative potential new treatments for unserved and underserved patient communities.  The company connects scientists, biopharmaceutical partners, patient groups, funders and philanthropists to deliver promising, transformative science to underserved patients.

TypePublic
Founded2017
HQStamford, CT, US
Websitespringworkstx.com

Latest Updates

Employees (est.) (Sept 2019)56(+8%)
Job Openings40
Revenue (FY, 2020)$35 M
Share Price (Oct 2021)$60.6(+7%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at SpringWorks Therapeutics

Saqib Islam

Saqib Islam

Chief Executive Officer, Director
Daniel S. Lynch

Daniel S. Lynch

Chairman
Alan Fuhrman

Alan Fuhrman

Director
Francis Perier

Francis Perier

Chief Financial Officer
Julie Hambleton

Julie Hambleton

Director
Freda Lewis-Hall

Freda Lewis-Hall

Director
Show more

SpringWorks Therapeutics Office Locations

SpringWorks Therapeutics has offices in Stamford and Durham
Stamford, CT, US (HQ)
100 Washington Blvd
Durham, NC, US
5310 S Alston Ave
Show all (2)

SpringWorks Therapeutics Financials and Metrics

SpringWorks Therapeutics Revenue

SpringWorks Therapeutics's revenue was reported to be $35 m in FY, 2020
USD

Net income (Q1, 2021)

(29.8m)

EBIT (Q1, 2021)

(29.8m)

Market capitalization (22-Oct-2021)

3.0b

Closing stock price (22-Oct-2021)

60.6

Cash (31-Mar-2021)

95.4m

EV

2.9b
SpringWorks Therapeutics's current market capitalization is $3 b.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

35.0m

General and administrative expense

1.9m8.6m16.7m29.5m

R&D expense

2.8m9.9m42.5m51.9m

Operating expense total

4.7m18.5m59.2m81.3m
Quarterly
USDQ3, 2019Q1, 2020Q2, 2020Q1, 2021

General and administrative expense

4.6m6.4m6.9m12.4m

R&D expense

10.7m9.7m12.9m17.4m

Operating expense total

15.3m16.1m19.8m29.8m

EBIT

(15.3m)(16.1m)(19.8m)(29.8m)
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

10.3m45.6m327.7m147.1m

Prepaid Expenses

270.0k1.4m3.7m4.9m

Current Assets

10.5m47.0m331.4m513.4m

PP&E

41.0k317.0k795.0k1.1m
Quarterly
USDQ2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Cash

185.3m343.8m311.1m226.7m95.4m

Prepaid Expenses

2.9m689.0k2.6m2.6m4.1m

Current Assets

188.2m344.5m313.6m293.8m481.5m

PP&E

799.0k820.0k885.0k1.1m1.0m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(4.6m)(17.8m)(58.3m)(45.6m)

Depreciation and Amortization

3.0k17.0k192.0k349.0k

Accounts Payable

283.0k491.0k1.9m(1.3m)

Cash From Operating Activities

(2.2m)(14.7m)(47.4m)(32.2m)
Quarterly
USDQ2, 2018Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Net Income

(6.6m)(25.3m)(42.1m)(15.3m)(35.2m)(29.8m)

Depreciation and Amortization

6.0k64.0k127.0k70.0k144.0k110.0k

Accounts Payable

871.0k1.4m1.4m(1.0m)(1.7m)879.0k

Cash From Operating Activities

(4.5m)(20.3m)(31.4m)(16.4m)(32.6m)(21.1m)
USDFY, 2017

Financial Leverage

0.9 x
Show all financial metrics

SpringWorks Therapeutics Operating Metrics

FY, 2019

Phase I Trials Products

2

Phase II Trials Products

1

Phase III Trials Products

1

Pre-Clinical Phase Products

1
Show all operating metrics

SpringWorks Therapeutics Acquisitions / Subsidiaries

Company NameDateDeal Size
SpringWorks Subsidiary 1, Inc
SpringWorks Subsidiary 2, Inc
SpringWorks Subsidiary 3, Inc
SpringWorks Subsidiary 4, Inc
SpringWorks Therapeutics, LLC
SpringWorks Therapeutics Operating Company, Inc.

SpringWorks Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

SpringWorks Therapeutics Online and Social Media Presence

Embed Graph

SpringWorks Therapeutics News and Updates

SpringWorks Therapeutics to Collaborate with Ab Magnitude on Target Identification and Discovery of Next-Generation Targeted Oncology Therapeutics

– SpringWorks to Utilize Pioneering Computational Modeling Approaches Developed by Yibing Shan, Ph.D., Previously Founding Member of DE Shaw Research and Leading Computational Structural Biologist –

SpringWorks Therapeutics to Collaborate with Leading Academic Institutions to Advance Portfolio of Next-Generation Mutation-Selective EGFR Inhibitors

- Portfolio is Currently in Lead Optimization and Includes Several Novel Approaches for Targeting Mutant EGFR that are Designed to Address Both De Novo Oncogenic Drivers and Emerging Resistance Mutations -

SpringWorks Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

STAMFORD, Conn., Sept. 07, 2021 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will participate in the H.C…

SpringWorks Therapeutics Enters into Research Collaboration with Leading Cancer Institute to Further Evaluate Nirogacestat as a BCMA Potentiator in Multiple Myeloma

-- Research to be Led by Constantine Mitsiades, M.D., Ph.D., at Dana-Farber Cancer Institute -- -- Research to be Led by Constantine Mitsiades, M.D., Ph.D., at Dana-Farber Cancer Institute --

SpringWorks Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Highlights

– Entered into Clinical Collaboration with Seagen to Evaluate Nirogacestat in Combination with SEA-BCMA and Dosed First Patients in Three Phase 1 Clinical Trials Evaluating Nirogacestat in Combination with BCMA Therapies Across Modalities in Patients with Relapsed or Refractory Multiple Myeloma –

SpringWorks Therapeutics to Present at the 12th Annual Wedbush PacGrow Healthcare Conference

STAMFORD, Conn., Aug. 03, 2021 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will participate in a Firesi…
Show more

SpringWorks Therapeutics Frequently Asked Questions

  • When was SpringWorks Therapeutics founded?

    SpringWorks Therapeutics was founded in 2017.

  • Who are SpringWorks Therapeutics key executives?

    SpringWorks Therapeutics's key executives are Saqib Islam, Daniel S. Lynch and Alan Fuhrman.

  • How many employees does SpringWorks Therapeutics have?

    SpringWorks Therapeutics has 56 employees.

  • What is SpringWorks Therapeutics revenue?

    Latest SpringWorks Therapeutics annual revenue is $35 m.

  • What is SpringWorks Therapeutics revenue per employee?

    Latest SpringWorks Therapeutics revenue per employee is $625 k.

  • Who are SpringWorks Therapeutics competitors?

    Competitors of SpringWorks Therapeutics include Repare Therapeutics, Permobil and Leica Microsystems.

  • Where is SpringWorks Therapeutics headquarters?

    SpringWorks Therapeutics headquarters is located at 100 Washington Blvd, Stamford.

  • Where are SpringWorks Therapeutics offices?

    SpringWorks Therapeutics has offices in Stamford and Durham.

  • How many offices does SpringWorks Therapeutics have?

    SpringWorks Therapeutics has 2 offices.